SEA-CD40 is under clinical development by Seagen and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect SEA-CD40’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their SEA-CD40 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
SEA-CD40 is under development for the treatment of solid tumors, non-small cell lung cancer (NSCLC), metastatic melanoma, metastatic uveal melanoma, Hodgkin lymphoma, indolent lymphoma including follicular lymphoma, diffuse large B-cell lymphoma and metastatic pancreatic ductal adenocarcinoma. It is administered through the intravenous route. The therapeutic candidate is a glyco-engineered non-fucosylated antibody which acts by targeting CD40. It is developed using sugar-engineered antibody (SEA) technology.
Seagen, formerly Seattle Genetics, is a biotechnology company that discovers, develops, and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs), including Adcetris (brentuximab vedotin), for the treatment of Hodgkin’s lymphoma, T-cell lymphomas and CD30-expressing lymphomas; Padcevtm (enfortumab vedotin-ejfv) for metastatic urothelial cancers; Tukysa (tucatinib) for the treatment of metastatic HER2-positive breast cancers, and Tivdak (tisotumab vedotin-tftv) for the treatment of certain metastatic cervical cancers. The company’s pipeline consists of novel therapies for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology, which targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.
Quick View SEA-CD40 LOA Data
|Highest Development Stage|